Mobile

Open label, non-randomized, phase II study on fractioned cyclophosphamide, vincristine, liposomal doxorubicin or doxorubicin, and dexamethasone (MY HYPER-CVAD) in the treatment of relapsed refractory ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003884-30

Open label, non-randomized, phase II study on fractioned cyclophosphamide, vincristine, liposomal doxorubicin or doxorubicin, and dexamethasone (MY HYPER-CVAD) in the treatment of relapsed refractory adult acute lymphoid leukemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and the anti-leukemic activity of Hyper-CVAD in patients with ALL, relapsed after or refractory to chemotherapy.

Critère d'inclusion

  • refractory adult acute lymphoid leukemia

Liens